| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5814567 | Neuropharmacology | 2014 | 8 Pages |
Abstract
Therefore, long-term hMSC efficacy in TBI is not dependent on immunosuppressive treatment. These findings could have important clinical implication since immunosuppression in acute TBI patients may increase their risk of infection and not be tolerated.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Francesca Pischiutta, Giovanna D'Amico, Erica Dander, Andrea Biondi, Ettore Biagi, Giuseppe Citerio, Maria Grazia De Simoni, Elisa R. Zanier,